IL-23在乳腺癌组织中的表达及其与患者临床病理特征的相关性

doi:10.11904/j.issn.1002-3070.2024.05.007

Abstract

Abstract: Objective The aim of this study was to investigate the expression of IL-23(IL-23)in breast cancer and its correlation with clinicopathological characteristics. Methods The tumor tissues and adjacent tissues of 100 patients with breast cancer diagnosed in Nanchong Central Hospital from January 2020 to December 2020 were collected.Immunohistochemistry and Real-Time PCR were used to determine the expression of IL-23 protein and mRNA in the two groups of tissues.The expression of IL-23 protein and mRNA in breast cancer tissues and adjacent tissues were compared,and the relationship between IL-23 expression and the clinicopathological characteristics of breast cancer was analyzed. Results IL-23 protein was mainly expressed in the membrane and cytoplasm of breast cancer cells.The expression of IL-23 protein and mRNA in breast cancer tissues were higher than those in adjacent tissues(P＜0.001).The expression of IL-23 protein and mRNA was positively correlated with the histological grade,T grade,clinical stage and Ki-67 expression of breast cancer,negatively correlated with the expression of ER and PR(P＜0.05),and was not related to neurovascular invasion,age and HER-2 expression in breast cancer(P＞0.05). Conclusion IL-23 may participate in the progression of breast cancer,and its expression is closely related to ER,PR,Ki-67 and other prognostic indicators,suggesting that its expression may be related to the prognosis,but it needs further experimental verification.

Key words: Interleukin-23, Estrogen receptor, Progesterone receptor, Breast cancer, Lymph node metastasis

CLC Number:

R737.9

YANG Minye, XIAN Tongcheng, LIU Jingjian, BIE Jun, WANG Jie, LUO Yi. The expression of IL-23 in breast cancer tissues and its correlation with clinicopathological characteristics[J]. Journal of Practical Oncology, 2024, 38(5): 323-329.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2024.05.007

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2024/V38/I5/323

References

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Han B,Zheng R,Zeng H,et al.Cancer incidence and mortality in China,2022[J].J Natl Cancer Center,2024,4(1):47-53.
3 Zhu JW,Charkhchi P,Adekunte S,et al.What is known about breast cancer in young women?[J].Cancers(Basel),2023,15(6):1917.
4 Comen EA,Norton L,Massagué J.Breast cancer tumor size,nodal status,and prognosis:biology trumps anatomy[J].J Clin Oncol,2011,29(19):2610-2612.
5 Mantovani A,Allavena P,Sica A,et al.Cancer-related inflammation[J].Nature,2008,454(7203):436-444.
6 Schinocca C,Rizzo C,Fasano S,et al.Role of the IL-23/IL-17 pathway in rheumatic diseases:an overview[J].Front Immunol,2021,12:637829.
7 Liu T,Li S,Ying S,et al.The IL-23/IL-17 pathway in inflammatory skin diseases:from bench to bedside[J].Front Immunol,2020,11:594735.
8 Suzuki H,Ogawa H,Miura K,et al.IL-23 directly enhances the proliferative and invasive activities of colorectal carcinoma[J].Oncol Lett,2012,4(2):199-204.
9 Xu X,Yang C,Chen J,et al.Interleukin-23 promotes the migration and invasion of gastric cancer cells by inducing epithelial-to-mesenchymal transition via the STAT3 pathway[J].Biochem Biophys Res Commun,2018,499(2):273-278.
10 Zang M,Li Y,He H,et al.IL-23 production of liver inflammatory macrophages to damaged hepatocytes promotes hepatocellular carcinoma development after chronic hepatitis B virus infection[J].Biochim Biophys Acta Mol Basis Dis,2018,1864(12):3759-3770.
11 Fukuda M,Ehara M,Suzuki S,et al.IL-23 promotes growth and proliferation in human squamous cell carcinoma of the oral cavity[J].Int J Oncol,2010,36(6):1355-1365.
12 Pellegrini C,Orlandi A,Costanza G,et al.Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments[J].PLoS One,2017,12(8):e0183415.
13 Gangemi S,Minciullo P,Adamo B,et al.Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients[J].J Cell Biochem,2012,113(6):2122-2125.
14 乳腺癌诊疗指南(2022年版)[J].中国合理用药探索,2022,19(10):1-26.
15 中国临床肿瘤学会乳腺癌专家委员会,中国抗癌协会乳腺癌专业委员会,中华医学会外科学分会乳腺外科学组.中国年轻乳腺癌诊疗专家共识(2022)[J].中华医学杂志,2023,103(6):387-403.
16 林燕,孙强,宋雨等.中国老年乳腺癌诊疗专家共识(2023版)[J].中国研究型医院,2023,10(5):1-8.
17 Giuliano AE,Connolly JL,Edge SB,et al.Breast cancer-major changes in the american joint committee on cancer eighth edition cancer staging manual[J].CA Cancer J Clin,2017,67(4):290-303.
18 王朋敏,王鑫,张晶,等.IL-23/Th17相关细胞因子在基底细胞癌中的表达水平及意义[J].中国皮肤性病学杂志,2020,34(5):530-533.
19 田红岭,侯玉柱,王若雨,等.IL-23生理病理学意义及信号通路[J].免疫学杂志,2014,30(6):555-559.
20 Najm A,McInnes IB.IL-23 orchestrating immune cell activation in arthritis[J].Rheumatology(Oxford),2021,60(Suppl 4):iv4-iv15.
21 Yan J,Smyth MJ,Teng MWL.Interleukin(IL)-12 and IL-23 and their conflicting roles in cancer[J].Cold Spring Harb Perspect Biol,2018,10(7):a028530.
22 Sheng S,Zhang J,Ai J,et al.Aberrant expression of IL-23/IL-23R in patients with breast cancer and its clinical significance[J].Mol Med Rep,2018,17(3):4639-4644.
23 Kunc M,Biernat W,Senkus-Konefka E.Estrogen receptor-negative progesterone receptor-positive breast cancer -“Nobody′s land” or just an artifact?[J].Cancer Treat Rev,2018,67:78-87.
24 Karihtala P,Kauppila S,Soini Y,et al.Oxidative stress and counteracting mechanisms in hormone receptor positive,triple-negative and basal-like breast carcinomas[J].BMC Cancer,2011,11:262.
25 Kim SJ,Saeidi S,Cho NC,et al.Interaction of Nrf2 with dimeric STAT3 induces IL-23 expression:Implications for breast cancer progression[J].Cancer Lett,2021,500:147-160.
26 Nawas AF,Mistry R,Narayanan S,et al.IL-1 induces p62/SQSTM1 and autophagy in ERα+/PR+BCa cell lines concomitant with ERα and PR repression,conferring an ERα-/PR-BCa-like phenotype[J].J Cell Biochem,2019,120(2):1477-1491.
27 Jiménez-Garduño AM,Mendoza-Rodríguez MG,Urrutia-Cabrera D,et al.IL-1β induced methylation of the estrogen receptor ERα gene correlates with EMT and chemoresistance in breast cancer cells[J].Biochem Biophys Res Commun,2017,490(3):780-785.
28 Schillace RV,Skinner AM,Pommier RF,et al.Estrogen receptor,progesterone receptor,interleukin-6 and interleukin-8 are variable in breast cancer and benign stem/progenitor cell populations[J].BMC Cancer,2014,14:733.
29 Shao N,Lu Z,Zhang Y,et al.Interleukin-8 upregulates integrin β3 expression and promotes estrogen receptor-negative breast cancer cell invasion by activating the PI3K/Akt/NF-κB pathway[J].Cancer Lett,2015,364(2):165-172.
30 Frasor J,El-Shennawy L,Stender JD,et al.NFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms[J].Mol Cell Endocrinol,2015,418 Pt 3(3):235-239.
31 Yerushalmi R,Woods R,Ravdin PM,et al.Ki67 in breast cancer:prognostic and predictive potential[J].Lancet Oncol,2010,11(2):174-183.
32 Nie W,Yu T,Sang Y,et al.Tumor-promoting effect of IL-23 in mammary cancer mediated by infiltration of M2 macrophages and neutrophils in tumor microenvironment[J].Biochem Biophys Res Commun,2017,482(4):1400-1406.

[1]	PANG Wanying, AN Jing, LIU Zhaoliang. The role and mechanism of TRIM24 in endocrine therapy resistance of breast cancer [J]. Journal of Practical Oncology, 2024, 38(6): 402-409.
[2]	ZHANG Yuqing, JING Jing, LIU Zhaoliang, AN Jing, AN Weiwei. The alternative splicing event of MZB1 is a potential biomarker of drug resistance in endocrine therapy of breast cancer [J]. Journal of Practical Oncology, 2024, 38(5): 313-322.
[3]	LIU Dong, ZHANG Taijuan, DANG Jifeng. The research progress of inflammatory reaction driving breast cancer metastasis [J]. Journal of Practical Oncology, 2024, 38(5): 336-341.
[4]	LI Qianni, XU Lingyan, LI Jian, YAO Xuepei, LIU Meina. Trend analysis of a longitudinal evaluation for multidimensional treatment quality of breast cancer [J]. Journal of Practical Oncology, 2024, 38(4): 213-220.
[5]	GAO Guangqiang, WANG Falin, LI Juan, TIAN Hong, GUO Sijia, YU Xiaolan, YANG Tingting, LIU Jiaren. β-Ionone suppresses breast cancer cell proliferation through the NF-κB pathway [J]. Journal of Practical Oncology, 2024, 38(4): 254-261.
[6]	SHAO Yuming, ZHU Kunbing, ZHANG Jie. Research progress of SP/NK-1R system in breast cancer [J]. Journal of Practical Oncology, 2024, 38(4): 268-272.
[7]	YIN Haiyan, CHUN Zhiming, MA Qiaojun, CHENG Han, DING Gaoheng, LIU Yuqin, ZHANG Haiyan. Epidemic characteristics of female breast cancer in cancer registration areas of Gansu province in 2019 and trend analysis from 2010 to 2019 [J]. Journal of Practical Oncology, 2024, 38(3): 141-148.
[8]	Breast Oncology Group of Heilongjiang Medical Association. Expert consensus on clinicopathological diagnosis of breast cancer with low expression of HER2 in Heilongjiang province(2024 edition) [J]. Journal of Practical Oncology, 2024, 38(2): 71-78.
[9]	MENG Fangang, CHEN Fei, ZHEN Lijun. Effects of DLX2 on proliferation,migration,invasion,apoptosis of breast cancer cells and characteristics of breast cancer stem cells [J]. Journal of Practical Oncology, 2024, 38(2): 88-95.
[10]	ZHENG Pengfei, DONG Liangpeng, GAO Yanxin, ZHANG Yifu, QIN Shuang. Effect of interleukin-38 to CD8⁺T lymphocyte function in patients with breast cancer [J]. Journal of Practical Oncology, 2024, 38(1): 30-36.
[11]	XIE Junling. Research progress of activated leukocyte adhesion molecule in breast cancer [J]. Journal of Practical Oncology, 2024, 38(1): 45-49.
[12]	FENG Churan, CAO Jianzhao, CHEN Ziyin, ZHANG Daxin, LU Hailing. Research progress on radiation-induced cardiac injury in breast cancer and its preventive measures [J]. Journal of Practical Oncology, 2023, 37(6): 513-518.
[13]	ZHAO Shilu, PANG Da. Bioinformatics screening and analysis of prognostic genes in breast cancer [J]. Journal of Practical Oncology, 2023, 37(5): 422-428.
[14]	CHU Sitong, XU Qingyong. Research progress on immunotherapy resistance mechanisms of triple-negative breast cancer [J]. Journal of Practical Oncology, 2023, 37(5): 449-453.
[15]	WANG Xinping, ZHANG Ziyun, WANG Xuedong. Research progress on the roles of non-coding RNA in chemotherapy resistance of breast cancer [J]. Journal of Practical Oncology, 2023, 37(5): 454-458.

The expression of IL-23 in breast cancer tissues and its correlation with clinicopathological characteristics

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments